GlassScriptPhysician profile
Melissa Ann Dove
NPI 1902854128
$40,746.07
in general payments reported to CMS, 2019-2025
52 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $20K · 2023: $6,231 · 2024: $1,325 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,400 · Food and Beverage: $3,864 · Education: $609 · Travel and Lodging: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,400.00 |
| Food and Beverage | $3,864.40 |
| Education | $608.95 |
| Travel and Lodging | $131.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $32,574.36 | 2021-2023 | Imbruvica, Epkinly |
| Janssen Biotech, INC. | $3,268.39 | 2022-2025 | Imbruvica, Rybrevant, Tecvayli |
| Seagen INC. | $552.02 | 2022-2023 | Padcev, Tukysa |
| Novartis Pharmaceuticals Corporation | $293.08 | 2021-2025 | |
| Pfizer INC. | $291.53 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $279.22 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $258.64 | 2022-2025 | Padcev, Xtandi |
| Daiichi Sankyo INC. | $247.36 | 2022-2025 | Enhertu, Datroway |
| Incyte Corporation | $190.26 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $179.42 | 2022-2025 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $171.06 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals LP | $160.12 | 2023-2025 | Enhertu, Imfinzi |
| Genentech USA, INC. | $157.88 | 2023-2025 | Phesgo, Polivy, Tecentriq Hybreza |
| Gilead Sciences, INC. | $150.44 | 2023-2024 | Trodelvy |
| Genzyme Corporation | $149.99 | 2022-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $110.07 | 2021-2023 | Lumakras |
| Abbvie INC. | $108.66 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Emd Serono, INC. | $86.15 | 2023-2025 | Tepmetko |
| Rigel Pharmaceuticals, INC. | $81.62 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Aveo Pharmaceuticals, INC. | $80.54 | 2023-2025 | Fotivda |
| Sun Pharmaceutical Industries INC. | $80.52 | 2023-2024 | Yonsa, Odomzo |
| Blueprint Medicines Corporation | $77.06 | 2022-2024 | Ayvakit |
| Jazz Pharmaceuticals INC. | $76.74 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $67.77 | 2023-2025 | Onivyde, Tazverik |
| Eisai INC. | $65.02 | 2023 | |
| Array Biopharma INC | $64.52 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Taiho Oncology, INC. | $60.63 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.27 | 2024-2025 | |
| Glaxosmithkline, LLC. | $55.25 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $55.12 | 2024-2025 | Pyrukynd |
| Regeneron Healthcare Solutions, INC. | $51.06 | 2022-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $45.28 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $45.14 | 2024-2025 | Ultomiris |
| Kyowa Kirin, INC. | $43.85 | 2021-2023 | Poteligeo |
| Cumberland Pharmaceuticals, INC. | $42.85 | 2023-2024 | Sancuso |
| Janssen Pharmaceuticals, INC | $39.31 | 2021-2024 | Xarelto |
| Stemline Therapeutics INC. | $37.30 | 2023-2024 | Orserdu |
| Deciphera Pharmaceuticals INC. | $30.01 | 2023-2025 | Qinlock, Romvimza |
| Exelixis INC. | $27.61 | 2025 | Cabometyx |
| Kite Pharma, INC. | $25.91 | 2024 | Yescarta |
| Apellis Pharmaceuticals, INC. | $25.45 | 2023 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $22.32 | 2022 | |
| Tersera Therapeutics LLC | $21.16 | 2023 | Zoladex |
| Pharmaessentia USA Corporation | $20.28 | 2023 | Besremi |
| Springworks Therapeutics, INC. | $20.25 | 2024 | Ogsiveo |
| Novo Nordisk INC | $18.25 | 2023 | |
| Syndax Pharmaceuticals, INC. | $17.67 | 2025 | |
| Melinta Therapeutics, LLC | $15.98 | 2024 | Rezzayo, Kimyrsa |
| Secura Bio, INC. | $15.54 | 2024 | Copiktra |
| Adc Therapeutics America, INC. | $14.46 | 2022 | |
| Cti Biopharma Corp. | $13.69 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Dove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.